Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS
Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …